Comment: This small but powerful study on dietary flaxseed is a great reminder that simple, well-tolerated dietary interventions can have profound biological effects in breast cancer. It also helps address a persistent misinterpretation, which is that flax can act negatively in breast cancer patients. The study shows a significant reduction in the Ki-67 index (cell […]
Comment: This large pooled analysis gives us several interesting and important pieces of information. Although this study was with breast cancer patients, there is no reason to believe it doesn’t apply to every cancer. The magnitude of risk associated with common, non-oncology drugs is genuinely alarming. PPI use, a near-universal practice for GI prophylaxis and […]
Comment: This meta-analysis provides important, ‘Moderate’ certainty evidence that supports a clinical approach that’s simple to implement. The key takeaway is the non-inferiority of intermittent androgen deprivation (IAD) regarding overall survival. While the summary notes minimal difference in overall quality of life, the qualitative data suggesting improvements in physical and sexual functioning is clinically significant. […]
Comment: Metronomic chemotherapy (mCHT) is a concept that’s been around, but it’s often overlooked in favor of high-dose regimens. This 2022 review from J. Clin. Med. brilliantly frames the evidence, separating the clear “lights”—like its low-toxicity profile—from the persistent “shadows” we still face, such as the lack of large randomized trials. For our frail or […]
Comment: This is an important pre-clinical study, adding another piece to the connection between levothyroxine and cancer. The finding that T4 promotes tumor growth not by direct cell stimulation, but by driving neoangiogenesis via the integrin αvβ3 receptor, is a critical piece of biologic plausibility. Of course, the major caveat is that this is a […]
Comment: This is a fascinating review of a complex topic. The key clinical pearl here is the paradoxical finding that treatment-induced hypothyroidism (from TKIs/ICPis) often correlates with a favorable prognosis. It underscores the need to closely monitor thyroid function in these patients—not just as a side effect to be managed, but as a potential prognostic […]
Comment: Unfortunately, this study confirms a persistent issue. We repeatedly see this major discrepancy between the “known unknowns”—the clinical uncertainties the FDA rightly identifies during expedited approvals—and what actually gets published in high-impact journals and translated into clinical guidelines like the NCCN. The result is that frontline oncologists are often making treatment decisions with an […]
Comment: This systematic review is, predictably, hampered by significant heterogeneity and an insufficient number of trials, preventing any definitive conclusions. However, an optimistic signal does emerge. The review strongly reinforces the primary value proposition of metronomic chemotherapy: an exceptionally favorable safety profile, with a striking lack of severe hematological toxicity. Furthermore, despite the mixed data, […]
Comment: While this study is flawed by its retrospective design and critical selection bias, we shouldn’t discard the core hypothesis. The authors are right to call the findings preliminary, but the concept of metronomic maintenance therapy remains highly compelling. The fact that such a strong Overall Survival signal (86.8% vs. 68.5%) was detected at all, […]
Comment: The MECCA trial, while certainly not practice-changing, provides an important signal for the potential of metronomic chemotherapy. The key takeaway is the therapeutic window. Achieving a 9-month PFS benefit and a positive OS trend with a regimen that produced Grade 3 adverse events in only 15.1% of patients is compelling. This highlights the central […]
